← All trials
NCT02690103
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2012
- Primary completion
- Jun 1, 2015
- Completion date
- Jun 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 37
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Cairo UniversityLead sponsor
- Cairo UniversityOverall official - principal investigator
- University of California, Los AngelesOverall official - principal investigator
- Cairo UniversityReponsible party - principal investigator
- Cairo UniversityStudy chair
- Cairo UniversityStudy director
- University of California, Los AngelesCollaborator
- Daiwa Pharmaceutical CorporationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.